GALD.SW
Galderma Group AG
$190.90
-0.15
(-0.08%)
Mkt Cap
44.52B
Volume
471,089
52W Range
136.3-193.9
Sector
Healthcare
Beta
-0.10
EPS (TTM)
2.25 CHF
P/E Ratio
84.77
Revenue (TTM)
4.34B CHF
Rev Growth (5Y)
+11.3%
EPS Growth (5Y)
N/A
Company Description
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.24B | 4.89B | 4.29B | 3.88B | 3.42B |
| Net Income | 642.16M | 254.35M | (56.23M) | (101.72M) | (154.27M) |
| EPS | 2.72 | 1.07 | -0.26 | -0.43 | -0.65 |
| Free Cash Flow | 1.03B | 213.00M | 43.35M | (49.77M) | 67.69M |
| FCF / Share | 4.35 | 0.90 | 0.18 | -0.21 | 0.28 |
| Operating CF | 1.19B | 488.00M | 165.00M | 114.93M | 195.66M |
| Total Assets | 13.39B | 12.62B | 12.26B | 12.42B | 12.53B |
| Total Debt | 2.75B | 2.76B | 4.83B | 5.66B | 5.67B |
| Cash & Equiv | 780.00M | 457.00M | 361.53M | 233.98M | 283.48M |
| Book Value | 8.15B | 7.79B | 5.28B | 4.47B | 4.53B |
| Return on Equity | 0.08 | 0.03 | -0.01 | -0.02 | -0.03 |
| Metric | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.07B | 2.78B | 2.64B | 2.12B | 606.13M | 1.11B | 1.05B | 2.15B | (906.55M) | 2.04B | 1.01B |
| Net Income | 434.28M | 422.69M | 209.31M | 176.64M | 32.93M | 23.56M | 23.40M | (63.32M) | 650,056 | 4.07M | 2.00M |
| EPS | 1.86 | 1.80 | 0.89 | 0.75 | 0.13 | 0.10 | 0.10 | -0.27 | -0.01 | 0.02 | 0.01 |
| Free Cash Flow | 504.71M | 528.97M | 548.08M | 322.10M | N/A | 29.08M | 28.88M | 273.12M | N/A | (248.11M) | (97.33M) |
| FCF / Share | 2.16 | 2.23 | 2.31 | 1.36 | N/A | 0.12 | 0.12 | 1.15 | N/A | -1.04 | -0.41 |
| Operating CF | 559.48M | 596.20M | 594.47M | 382.28M | N/A | 44.11M | 43.82M | 348.08M | N/A | (168.79M) | (82.86M) |
| Total Assets | 13.56B | 13.39B | 12.88B | 12.62B | N/A | 12.61B | 12.53B | 12.27B | N/A | N/A | 0 |
| Total Debt | 2.70B | 2.75B | 2.85B | 2.76B | N/A | 2.95B | 2.94B | 4.83B | N/A | N/A | 0 |
| Cash & Equiv | 841.26M | 780.00M | 458.00M | 457.00M | N/A | 386.00M | 383.44M | 236.66M | N/A | N/A | (233.70M) |
| Book Value | 8.24B | 8.15B | 7.73B | 7.79B | N/A | 7.65B | 7.60B | 5.37B | N/A | N/A | 4.46B |
| Return on Equity | 0.05 | 0.05 | 0.03 | 0.02 | N/A | 0.00 | 0.00 | -0.01 | N/A | N/A | 0.00 |
GALD.SW News
